Loading clinical trials...

Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects | Clinical Trials | Clareo Health

COMPLETEDNA

Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

NCT00166322•Ludwig-Maximilians - University of Munich

View on ClinicalTrials.gov

Summary

This study is an investigation of the dopaminergic neurotransmission in patients with schizophrenia, patients at risk for the development of schizophrenia, and healthy controls using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging technique under amphetamine challenge.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Clinical diagnosis of schizophrenia (currently unmedicated)
•Subjects at risk for the development of schizophrenia (prodromal symptoms)
•Healthy subjects
•Written informed consent

Exclusion Criteria

•Neurological or severe somatic disorders
•Women during pregnancy or lactation
•Occupational exposition to radiation \> 15mSv
•Medication known to interfere with IBZM
•Contraindications for the use of amphetamine challenge

Locations (2)

Dept. of Psychiatry

Munich, Germany

Dept. of Nuclear Medicine

Munich, Germany

Key Dates

Start Date

January 1, 2004

Primary Completion Date

December 1, 2007

Completion Date

December 1, 2007

Last Updated

May 7, 2008

Enrollment

ACTUAL participants

Conditions

Schizophrenia

Interventions

IBZM-SPECT (bolus and constant infusion paradigm)

PROCEDURE

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 7, 2008Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques

Brain Stimulation to the Hippocampus in Schizophrenia